Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer
Final analysis of Dana-Farber co-led phase 3 FLAURA2 study underscore benefits of adding chemotherapy to existing standard first line therapy with an EGFR-TKI
2025-10-17
(Press-News.org) BERLIN October 17, 2025 – Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib alone. The finding is based on an analysis of the complete data from the phase 3 global FLAURA2 study, co-led by researchers from Dana-Farber Cancer Institute and Gustave Roussy (Grand Paris, Villejuif, France). Median overall survival was 47.5 months in the osimertinib plus platinum–pemetrexed group versus 37.6 months in the osimertinib monotherapy group.
The results of the FLAURA2 trial were presented today at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, and published simultaneously in the New England Journal of Medicine.
“This is the longest overall survival in this patient population that we've seen in any clinical trial to date. It shows that combination therapies can lead to improvements over a single agent. This data helps establish osimertinib plus chemotherapy as standard of care first-line therapy,” says ESMO presenter and co-principal investigator Dr. Pasi A. Jänne, director of the Lowe Center for Thoracic Oncology at Dana-Farber.
Jänne presented data showing that the combination could benefit subgroups of patients with poor prognoses. For example, the group of patients with central nervous system metastases who received osimertinib plus platinum–pemetrexed had median overall survival of 40.9 months compared to 29.7 months for those who received osimertinib alone.
About 10-15% of patients in the US and 50% of patients in Asia with NSCLC harbor epidermal growth factor receptor (EGFR) mutations in their tumors. The mutation fuels the growth of the cancer.
The FLAURA2 trial tested adding platinum–pemetrexed up-front in combination with osimertinib to stave off recurrence observed with osimertinib monotherapy. Osimertinib is a third generation EGFR-tyrosine kinase inhibitor (EGFR-TKI).
The combination was approved by the U.S. Food and Drug Administration (FDA) in February 2024 based on FLAURA2 results showing the combination lengthened progression free survival compared to osimertinib alone. This final report of extended overall survival with the combination underscores the benefit of the combination for patients, including patients with a poor prognosis.
“This is a very exciting development,” says Jänne. “These results show the benefits of a combination when started from the very beginning of treatment. I think there's opportunity to use this as a platform to develop additional combination therapies that enhance efficacy from the start of treatment.”
Patients receiving the combination experience additional adverse events associated with the added chemotherapy. Side effects include nausea, vomiting, fatigue, and bone marrow toxicities and are most pronounced during the first few months of treatment that includes platinum chemotherapy but lessen during maintenance therapy with osimertinib and pemetrexed.
“There are now multiple options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer, including combination therapies and monotherapies, which is a wonderful thing,” says Jänne. “Patients have choices, and shared decision-making with patients will be essential to balance the greatest survival benefit against potential side effects.”
Funding: This study was funded by AstraZeneca.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.
Dana-Farber is the only hospital nationwide with a top 3 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.
As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,200 clinical trials.
###
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-10-17
The Florida Atlantic University Harbor Branch Oceanographic Institute’s Queen Conch Lab, led by research professor Megan Davis, Ph.D., has been named the recipient of the 2025 Responsible Seafood Innovation Award in Aquaculture from the Global Seafood Alliance (GSA).
The award honors the Queen Conch Lab’s development of mobile lab hatcheries designed to help restore the threatened Caribbean queen conch. These self-contained, trailer-based hatcheries bring advanced aquaculture capabilities to coastal communities across the Caribbean, many of which lack traditional infrastructure. This innovation is not only helping to rebuild wild ...
2025-10-17
A new review published in the Journal of Intensive Medicine on 25 July, 2025 and led by Dr. Alice Jacquens and Dr. Clara Perrault from Pitié Salpêtrière Hospital, Paris, France, sheds light on an under-recognized complication of traumatic brain injury (TBI): post-traumatic vasospasm (PTV).
PTV is a sudden narrowing of brain arteries that can lead to stroke and long-term neurological damage. It may affect up to 60% of TBI patients but is often missed, especially in intensive care units where ...
2025-10-17
King Abdullah University of Science and Technology (KAUST; Saudi Arabia) researchers have set a record in microchip design, achieving the first six-stack hybrid CMOS (complementary metal-oxide semiconductor) for large-area electronics. With no other reported hybrid CMOS exceeding two stacks, the feat marks a new benchmark in integration density and efficiency, opening possibilities in electronic miniaturization and performance.
Among microchip technologies, CMOS microchips are found in nearly all electronics, from phones and televisions to satellites and medical devices. Compared with conventional silicon chips, hybrid CMOS microchips hold greater promise ...
2025-10-17
Large language models (LLMs) can store and recall vast quantities of medical information, but their ability to process this information in rational ways remains variable. A new study led by investigators from Mass General Brigham demonstrated a vulnerability in that LLMs are designed to be sycophantic, or excessively helpful and agreeable, which leads them to overwhelmingly fail to appropriately challenge illogical medical queries despite possessing the information necessary to do so. Findings, published in npj Digital Medicine, demonstrate that targeted training and fine-tuning can ...
2025-10-17
CAMBRIDGE, MA -- Before cells can divide, they first need to replicate all of their chromosomes, so that each of the daughter cells can receive a full set of genetic material. Until now, scientists had believed that as division occurs, the genome loses the distinctive 3D internal structure that it typically forms.
Once division is complete, it was thought, the genome gradually regains that complex, globular structure, which plays an essential role in controlling which genes are turned on in a given cell.
However, a new study from MIT shows that in fact, this picture is not fully accurate. ...
2025-10-17
Electrical engineers at Duke University have demonstrated the ability to print fully functional and recyclable electronics at sub-micrometer scales. The technique could impact the more than $150 billion electronic display industry and its environmental impact while providing a toehold for U.S. manufacturing to gain traction in a vital and quickly growing industry.
The research appears October 17 in the journal Nature Electronics.
“If we want to seriously increase U.S.-based manufacturing in areas dominated by global competitors, we need transformational technologies,” said Aaron ...
2025-10-17
Hamilton, ON (October 17, 2025) – A new study led by researchers at McMaster University reveals that hidden fat deep inside the abdomen and liver may quietly damage arteries, even in people who appear healthy.
The findings, published in Communications Medicine on October 17, 2025, challenge the long-standing reliance on body-mass index (BMI) as a measure of obesity and offer fresh insight into how hidden fat contributes to heart disease.
Visceral fat (the kind that wraps ...
2025-10-17
Ever wonder what happens to those old, broken electronics after tossing them? How about how new ones are being produced despite dwindling resources? The seemingly endless supply of gadgets hides an increasingly critical problem, limited raw resources.
Electronics, optical fibers, and superconducting materials heavily rely on rare earth metals, but such limited resources lack innovative recycling solutions. Various methods do exist for metal recovery, but technology with low environmental impact and costs is rising in demand.
Fortunately, an answer may have been found in the common kitchen ingredient, baker’s yeast. ...
2025-10-17
A new study by researchers from Sichuan Agricultural University and international collaborators provides the most comprehensive evidence to date that biochar, a charcoal-like substance made from organic materials, plays a crucial role in faster, cleaner composting.
By analyzing data from 125 studies across the world, the research team showed that adding biochar to composting systems significantly boosts compost quality while slashing harmful greenhouse gas emissions. The findings, published in Biochar X, could help scale up sustainable waste management and climate-friendly agriculture.
“Biochar ...
2025-10-17
Pulmonary fibrosis is a deadly disease in which the lungs become thickened and scarred, gradually losing their ability to deliver oxygen to the body. Now, scientists at UC San Francisco have identified a key cellular switch that drives this process — and found a way to block it in mice.
The new therapy, which appears Oct. 15 in Journal of Clinical Investigation, works by preventing healthy lung cells from converting to a more harmful cell type. In mice with pulmonary fibrosis, the treatment ...
LAST 30 PRESS RELEASES:
[Press-News.org] Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer
Final analysis of Dana-Farber co-led phase 3 FLAURA2 study underscore benefits of adding chemotherapy to existing standard first line therapy with an EGFR-TKI
